Recently, Reindeer Biotech announced that the Australian Therapeutic Goods Administration (TGA) has formally accepted its application for marketing authorization of its CAR-T cell product, Ikiorenzai Injection (FUCASO), for inclusion in the Australian Therapeutic Goods Register (ARTG) and entered the evaluation stage for the treatment of adult patients with relapsed/refractory multiple myeloma (r/r MM) who have progressed after at least three lines of prior therapy.

This event is not only a milestone in the internationalization of a single company, but also reflects a profound shift in the strategic positioning of Chinese innovative drugs in Australia. For a long time, Australia has been a "hotbed" and "stepping stone" for Chinese pharmaceutical companies to conduct early clinical trials, but there are very few cases of commercialization and listing in Australia.

As clinical benefits gradually reach their peak and market competition intensifies, Chinese pharmaceutical companies, represented by Reindeer Biotech, are attempting to bridge the gap between clinical data and commercial value, transforming Australia from a "testing ground" for validating global data into a "new battlefield" for realizing commercial value and accumulating international regulatory credibility.

01

FUCASO Australia's application has been accepted.
Industry signals in a product timeline

FUCASO is the world's first fully human targeted BCMA CAR-T cell therapy product independently developed by Reindeer Biotech. It was approved for marketing in China in 2023 for the treatment of adult patients with r/r MM who have progressed after at least 3 lines of prior therapy.

As the world's first commercially available fully human CAR-T product, FUCASO has received regulatory approval in multiple countries and regions since its initial market launch, thanks to its significant efficacy and safety. In January 2025, the Health Sciences Authority (HSA) of Singapore accepted FUCASO's New Drug Application (NDA), and in June 2026, Singapore officially approved FUCASO for marketing. In February 2025, the Hong Kong Department of Health accepted the NDA, and in November 2025, Hong Kong approved its marketing. In March 2025, Macau approved its marketing. Simultaneously, FUCASO has also received Orphan Drug Designation (ODD) from the Ministry of Food and Drug Safety (MFDS) of Korea and the Saudi Arabian Food and Drug Administration (SFDA), accelerating its local registration and approval process. Building on this, FUCASO has entered the TGA evaluation stage in Australia, signifying a further extension of its international footprint into the Oceania market.

It should be noted that in the r/r MM track, Johnson & Johnson/Legend Biopharma's CARVYKTI (Cidadex Olenza, BCMA CAR-T cell therapy) was approved in the Australian market in June 2023, and its indications are highly consistent with FUCASO's application.

This means that if FUCASO is approved in the future, it will be entering a high-barrier market. However, FUCASO also has a differentiated basis. It is the world's first commercially available fully human BCMA-targeting CAR-T, while CARVYKTI's scFv is a humanized mouse sequence. The fully human structure may theoretically lead to lower immunogenicity and longer in vivo persistence, but this advantage still needs to be supported by real-world data and larger-scale clinical validation.

Clinical data from the FUMANBA-1 study, with a 36-month follow-up, showed that among 109 treated r/r MM patients, the overall response rate was 96.3%, the complete response rate was 83.2%, and the median progression-free survival was 30.5 months. In the subgroup of patients who had not previously received CAR-T therapy, the overall response rate was 98.9%, the complete response rate was 88.4%, and the median progression-free survival was 35.9 months. The median overall survival has not yet been reached.

These data provide a foundation for FUCASO's participation in international competition. For FUCASO itself, entering the Australian market is just a natural step in its international strategy; but in the grand scheme of Chinese innovative drugs going global, this acceptance in Australia is a milestone: Australia, where Chinese pharmaceutical companies used to flock to conduct clinical trials, is now becoming a new battleground for everyone to rush into commercialization.

02

Why did Australia become the first
China's "Clinical Hotbed" for Innovative Drugs

Since BeiGene first launched its clinical trials in Australia in 2014, Australia has gradually become an important destination for Chinese pharmaceutical companies' early-stage overseas clinical development. According to public data, as of August 2026, more than 70 Chinese innovative pharmaceutical companies have conducted clinical trials in Australia, covering multiple popular fields such as ADCs, bispecific/triple antibodies, siRNA, GLP-1, CAR-T, vaccines, radiopharmaceuticals, and CNS (Chinese scientific and technological innovation) research. Among them, about 70% of the projects are in Phase I clinical trials.

Chinese pharmaceutical companies choose Australia as an important early-stage testing ground for their overseas expansion because Australia possesses several conditions that highly align with the globalization needs of innovative drugs in the early clinical stages.

The first key element: Speed. One of the most expensive costs in innovative drug clinical development is time. In the United States, new drug clinical trials typically involve stages such as IND application, pre-IND communication, research center initiation, and patient enrollment, resulting in a lengthy overall process. FDA approval for new drug clinical trial applications takes 60 business days, and including pre-IND meetings, the time from submission to actual clinical trial initiation often exceeds six months.

Australia offers a lighter alternative. Local clinical trials can utilize the CTN (Clinical Trial Notification) model: after obtaining approval from the human research ethics committee, the company can then file with the TGA to commence the trial. Compared to the US IND model, this process is simpler and more suitable for rapid initiation of early-stage clinical trials. Under the CTN pathway, the regulatory filing process can be completed within 5 to 7 business days. Early-stage projects can often progress from ethical review to actual initiation within 4 to 8 weeks.

This speed is clearly demonstrated in specific cases. BeiGene's zanubrutinib initiated its first patient enrollment in Australia in 2014, completing the process from protocol determination to first patient enrollment in just three months, and dose escalation within six months. For companies with limited cash flow that need to obtain first-human data as quickly as possible, Australia's speed is of paramount importance.

The second advantage: Recognition. The second major advantage of Australian clinical trials is the international recognition of the data. The Australian clinical research system follows ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) standards and adopts GCP (Good Clinical Practice). This means that clinical data generated in Australia is not merely "overseas patient data," but can be accepted by mainstream regulatory agencies such as the FDA and EMA to support international applications and regulatory communication.

This is also a key difference between Australia and some low-cost emerging markets. While some Southeast Asian countries have advantages in cost and enrollment speed, their regulatory frameworks and compliance with ICH-GCP vary widely, and the FDA and EMA may have hidden barriers when reviewing data. Therefore, the value of early-stage clinical trials in Australia goes beyond simply "conducting trials overseas"; it helps Chinese pipelines move more quickly from "Chinese assets" to "global assets." For example, the domestically developed antibiotic MRX-5, developed by Micoco Pharmaceuticals, directly initiated Phase IIa clinical trials in the United States based on Phase I clinical trial data completed in Australia.

In business development (BD) transactions, this international recognition is equally important. In December 2025, Fosun Pharma entered into a global exclusive licensing agreement with Pfizer, granting Pfizer the global rights to its oral small molecule GLP-1 receptor agonist YP05002 for a total price of up to US$2.085 billion. At the time the agreement was signed, the drug was already in Phase I clinical trials in Australia, reducing the buyer's decision-making risk.

The third advantage: cost savings. Australia's third advantage in attracting Chinese pharmaceutical companies is its cost and R&D tax incentives. The Australian government has a research and development tax incentive policy. For eligible companies, especially SMEs with annual turnover below AUD 20 million, up to 43.5% of their R&D expenditures can be refunded.

This policy has directly altered the cost structure of early-stage clinical trials in Australia. Combined with R&D tax incentives, the overall cost of Phase I clinical trials in Australia can be reduced by approximately 50% to 60% compared to the United States, which is why Australia is particularly suitable for Phase I clinical trials.

Australia attracts Chinese pharmaceutical companies not solely through policies and cost advantages. After years of development, it has established a relatively complete early-stage clinical service ecosystem. In terms of CROs and Phase I clinical trial providers, companies such as Nucleus Network, CMAX, Novotech, and George Clinical have long been active in the Australian early-stage clinical market. Research and medical infrastructure are also significant strengths of Australia.

Australia boasts healthcare industry clusters such as the Adelaide Biomedical City, the Melbourne Biomedical District, and the Gold Coast Health and Knowledge Industry Park, and possesses a strong research foundation in areas such as infectious diseases, immune diseases, neuroscience, and cancer. Furthermore, the Medicare public healthcare system and the national electronic health record system provide essential conditions for clinical research and medical data management.

According to publicly available data, from 2019 to 2023, Australia hosted 38.8% of the overseas Phase I clinical trials conducted by Chinese pharmaceutical companies, second only to the United States; that is to say, nearly 4 out of every 10 overseas Phase I clinical trials conducted by Chinese pharmaceutical companies took place in Australia.

Another side of this clinical hotspot: Few Chinese innovative drugs have been approved for marketing in Australia.

A booming clinical market in Australia does not automatically equate to commercial maturity. In recent years, the number of innovative Chinese drugs approved for marketing in Australia has remained limited.

Currently, the types of domestically produced drugs approved for marketing by the Therapeutic Goods Administration (TGA) mainly cover chemical drugs, biological drugs, and traditional Chinese medicines. Representative products include BeiGene's zanubrutinib (mantle cell lymphoma and Waldenström macroglobulinemia), Henlius' Hanquyou (trastuzumab biosimilar for HER2-positive breast cancer and gastric adenocarcinoma), Innovent Biologics' orelabrutinib (BTK inhibitor for relapsed/refractory mantle cell lymphoma), Junshi Biosciences' toripalimab (nasopharyngeal carcinoma), and Zhong Sheng Pharmaceutical's traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases—Compound Thrombolytic Agent.

Besides this, there are not many clearly identifiable cases of Chinese innovative drugs being approved in Australia. According to the "2026 China Innovative Drug Overseas Export Industry Research Report" released by the industry, as of the end of 2024, a total of 18 domestically produced original innovative drugs had been approved overseas, the vast majority of which were concentrated in Europe and the United States.

Therefore, in the past, Australia's main role for Chinese innovative drugs was not as a destination for market launch, but as a frontier for clinical trials. Now, a new script is slowly unfolding, and Australia is becoming a "commercial battlefield."

Why is Australia becoming a new "battleground" for commercialization?

Australia's transformation from a "springboard" to a "battlefield" is the result of multiple factors. Australia's population is currently around 28 million, which, in terms of population alone, cannot compare to the United States or the European Union. However, the Australian market has several characteristics that cannot be ignored.

First, pharmaceutical spending continues to grow. The Australian pharmaceutical market was worth approximately US$24.7 billion in 2024, and consulting firm IMARC predicts it will reach US$31.1 billion by 2033. Second, the burden of disease and an aging population drive sustained demand. Australia's aging population is significant, with the proportion of the population aged 65 and over expected to reach 17%; demand continues to grow in areas such as cancer, cardiovascular, metabolic, and immune regulation. Third, Australia relies on imports for approximately 90% of its medicines , as well as most raw materials; currently, there is a shortage of about 400 medicines, of which about 30 are listed as critical medicines.

On the payment side, Australia's Pharmaceutical Benefits Scheme (PBS) provides subsidies for prescription drugs listed in the PBS to citizens and permanent residents , ensuring their access to essential medications. Currently, the PBS covers approximately 90% of the prescription drug market. In the 2022-2023 financial year, the PBS subsidized approximately 223.1 million prescriptions, with total expenditures reaching AUD 17 billion, accounting for 60% of the national drug costs.

This means that Australia is not just a "clinical springboard," but also a niche market with real payment capacity, import dependence, and high-value drug channels.

03

Conclusion:
What does this mean for Chinese pharmaceutical companies?

Of course, Australia is ultimately just a market of about 28 million people, with limited capacity, and cannot replace the United States or the European Union. But just as it served as a springboard for clinical trials over the past decade, its value today as a commercial battleground lies precisely in its "small but complete" ecosystem: strict regulation, international recognition, a payment system, and genuine competition.

For Chinese innovative pharmaceutical companies, being able to prove themselves in such a market means they can have a more secure position at the global stage. Australia may not be the final destination, but it is becoming an increasingly important stop on the road for Chinese pharmaceutical companies to go global.

https://news.yaozh.com/archive/48981.html